Slingshot members are tracking this event:

Phase 3 Data of Prostvac for Prostate Cancer Due Second Half of 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Additional Relevant Details Bavarian Nordic, in partnership with Bristol-Myers Squibb, is developing Prostvac for treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer.  Final data is expected in 2017, but interim analysis confirms the study will proceed without modification.
Additional Relevant Details Update on Jan 4 2017: Initially expected in 2017, the timeline got narrowed down to second half of 2017.
"The company maintains its previous guidance that full data is expected within this year, albeit in the second half of 2017, with the third interim analysis likely to occur around mid-2017. This estimate is based on a decline in the number of average monthly events currently seen in the PROSPECT study."
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 14, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Prostvac, Phase 3 Final Data, Prostate Cancer, Cancer  immunotherapy